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Purpose—To analyze final long-term survival and clinical outcomes from the randomized phase
III study of sunitinib in gastrointestinal stromal tumor (GIST) patients after imatinib failure; to
assess correlative angiogenesis biomarkers with patient outcomes.
Experimental Design—Blinded sunitinib or placebo was given daily on a 4-week-on/2-week-
off treatment schedule. Placebo-assigned patients could cross over to sunitinib at disease
progression/study unblinding. Overall survival (OS) was analyzed using conventional statistical
methods and the rank-preserving structural failure time (RPSFT) method to explore crossover
impact. Circulating levels of angiogenesis biomarkers were analyzed.
Results—In total, 243 patients were randomized to receive sunitinib and 118 to placebo, 103 of
whom crossed over to open-label sunitinib. Conventional statistical analysis showed that OS
converged in the sunitinib and placebo arms (median 72.7 versus 64.9 weeks; hazard ratio [HR],
0.876; P = 0.306) as expected, given the crossover design. RPSFT analysis estimated median OS
for placebo of 39.0 weeks (HR, 0.505, 95% CI, 0.262–1.134; P = 0.306). No new safety concerns
emerged with extended sunitinib treatment. No consistent associations were found between the
pharmacodynamics of angiogenesis-related plasma proteins during sunitinib treatment and clinical
outcome.
Conclusions—The crossover design provided evidence of sunitinib clinical benefit based on
prolonged time to tumor progression during the double-blind phase of this trial. As expected,
following crossover there was no statistical difference in OS. RPSFT analysis modeled the
absence of crossover, estimating a substantial sunitinib OS benefit relative to placebo. Long-term
sunitinib treatment was tolerated without new adverse events.
Keywords
Phase III; GIST; sunitinib; antiangiogenic; tyrosine kinase inhibitor
Introduction
The key pathogenic event causing the neoplastic phenotype for the majority of
gastrointestinal stromal tumors (GISTs) has been shown to be mutation of the genes
encoding KIT (stem cell factor receptor) or platelet-derived growth factor receptor alpha
(PDGFR-α), resulting in constitutively activated signaling through these receptor tyrosine
kinases (RTKs; refs. 1–3). The oral multitargeted RTK inhibitor sunitinib malate targets a
number of RTKs, including KIT, PDGFRs-α and -β, and vascular endothelial growth factor
receptors (VEGFRs)-1, -2, and -3 (4–9), thereby blocking key kinases involved in
maintaining the survival and proliferation of GIST cells and signals of tumor-related
angiogenesis.
Previously reported results of the planned interim analysis of a double-blind, placebo-
controlled, randomized phase III study of sunitinib in patients with GIST following imatinib
failure demonstrated significant clinical benefit from sunitinib treatment with acceptable
safety (10). Based on these results, sunitinib received multinational regulatory approval for
the treatment of advanced imatinib-resistant or -intolerant GIST (9, 10).
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Following unblinding due to the positive impact of sunitinib on time to tumor progression
(TTP), all patients randomized to receive placebo were offered the opportunity to cross over
to open-label sunitinib treatment (10). This trial was designed knowing that crossover to an
active agent would necessarily confound any estimate of treatment effect on overall survival
(OS) using conventional statistical methods. We now report final results from this study,
including OS and toxicities observed with long-term sunitinib administration; OS was
analyzed using both conventional statistical techniques and an exploratory method to
estimate this effect of crossover on survival. To expand on the previously reported finding
that the extent of reduction in plasma soluble (s)KIT during sunitinib treatment correlated
strongly with improved clinical outcome in this study (11), we examined possible
associations between plasma levels of the angiogenesis-related proteins VEGF-A,
sVEGFR-2, and sVEGFR-3 and sunitinib efficacy in a subset of patients.
Materials and Methods
Study population
The study population comprised adults with histologically proven GIST for whom prior
imatinib treatment had failed due to resistance or intolerance, an Eastern Cooperative
Oncology Group performance status (ECOG PS) ≤1, and adequate hepatic, renal, and
cardiac function as described previously (10).
Study design and treatment
Patients were randomized 2:1 to receive double-blind treatment in repeated 6-week cycles of
4 weeks of daily sunitinib (50 mg) or placebo followed by 2 weeks off treatment
(Supplementary Fig. S1). At the time of disease progression or termination of the double-
blind phase of the study (whichever occurred first), treatment assignments were unblinded,
and patients randomized to sunitinib were permitted to continue treatment. Eligible patients
randomized to placebo were allowed to cross over to open-label sunitinib treatment. The
study conformed to the principles of the Declaration of Helsinki and Good Clinical Practice
guidelines. The institutional review boards of participating study centers approved the
protocol. All participants provided written informed consent.
Clinical assessments
The primary efficacy endpoint of this study was TTP. Secondary efficacy endpoints
included OS, progression-free survival (PFS), and overall confirmed objective response rate
(ORR). Tumor imaging studies, which have been described previously (10), were performed
at baseline, on day 28 of each treatment cycle, and at the end of treatment, or more
frequently as required; disease assessments were made using Response Evaluation Criteria
in Solid Tumors (12). Primary analysis of response-based efficacy endpoints utilized
assessments from an independent, third-party, core imaging laboratory.
Safety was evaluated by analysis of adverse events (AEs), physical examinations, vital
signs, ECOG PS, laboratory tests, and cardiac function assessments as previously described
(10). AEs were graded using National Cancer Institute Common Terminology Criteria for
Adverse Events version 3.0.
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Assessment of plasma protein biomarkers
VEGF-A, sVEGFR-2, and sVEGFR-3 were chosen for evaluation on the basis of their
relationship to known sunitinib molecular targets, their established roles in VEGF-related
signaling and angiogenesis, and on reproducible plasma pharmacodynamics obtained in
sunitinib trials in a number of tumor types (13–15). Blood was collected in heparinized tubes
pre-dose at baseline, on days 14 and 28 of cycle 1, and on days 1 and 28 of subsequent
cycles. Plasma samples were stored at −70°C; storage duration was within the period
covered by stability assessment for each protein analyzed. Plasma concentrations of VEGF-
A, sVEGFR-2, and sVEGFR-3 were determined using enzyme-linked immunosorbent assay
(ELISA) kits from R&D Systems (Minneapolis, MN). The VEGF-A assay measured the
VEGF-A165 and VEGF-A121 isoforms. Plasma sVEGFR-2 and sVEGFR-3 were measured
using assays that detect the extracellular domains of the respective full-length receptors
without cross-reactivity. The sVEGFR-2 and sVEGFR-3 assays were calibrated against
recombinant proteins consisting of extracellular receptor domains. All assays were run under
Good Laboratory Practice conditions, and performance specifications of each ELISA were
validated for their intended purpose according to established guidelines (16).
In the placebo arm, plasma protein values obtained after crossover to sunitinib treatment
were excluded from analysis and TTP values from these patients were censored at crossover.
The correlative analyses reported here represent evaluations of specific individual biomarker
hypotheses as described above, and corrections for multiple comparisons were not applied.
The numbers of samples analyzed (at baseline: sunitinib arm, n = 68–88; placebo arm, n =
33–60) were comparable to those analyzed in earlier sunitinib trials in several tumor types
(13–15).
Statistical analyses
Efficacy analyses were based on the intent-to-treat (ITT) population (all patients
randomized), comparing the treatment arms as randomized. Safety analyses were conducted
on the per-protocol patient population (who received ≥1 dose of assigned blinded study
treatment) and the population that received ≥1 dose of open-label sunitinib treatment
(Supplementary Fig. S2). Time-to-event data (including those stratified by exploratory
biomarkers) were analyzed using the Kaplan-Meier method, log-rank test, and Cox
proportional hazards model.
Additionally, OS was analyzed using the rank-preserving structural failure time (RPSFT)
method (17). This method assumes that treatment does not change the order of events (i.e., it
preserves rank), but alters the time at which events occur, with treatment prolonging survival
by a multiplicative factor (exp[ψ] in the model). Thus, the structural or causal assumption of
this failure-time (i.e., survival-time) model is that time is proportional for an individual
patient (in contrast to the assumption underlying the Cox proportional hazards model, in
which there is a multiplicative relationship between the hazard rates of any two patients,
which is constant over time). This analysis (performed on the ITT population) accounts for
crossover by estimating the treatment effect in the placebo arm (as randomized) by relating a
patient’s observed event time to the treatment-effect parameter ψ and the event time that
would reasonably be estimated to occur in the absence of crossover. If T is the observed
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event time for a patient who crossed over from placebo to open-label sunitinib treatment and
Tp is the time on placebo, then
where U is the event time that would have been observed if no treatment had been given and
exp(ψ) is the multiplicative effect of having started treatment. The patients’ times on
treatment after crossover (T–Tp) are adjusted to reflect what would have happened if they
had stayed on placebo. ψ is estimated by computing U for a range of possible values of ψ
and finding the value that yields a zero in the log-rank test statistic when the two treatment
arms are compared using time U (since one would expect no difference between the two
arms prior to treatment due to randomization).
The RPSFT method does not require that crossover and prognosis are independent, and
estimation of U would have incurred this type of bias without proper handling (18, 19). The
recensoring procedure described by Robins and Tsiatis (14) was therefore employed to
overcome this potential bias. The hazard ratio (HR) comparing treatment with sunitinib and
placebo following RPSFT analysis was estimated by performing a Cox regression analysis
on the observed event times in the sunitinib arm and the estimated U values for crossover
patients or the observed event times for other patients in the placebo arm. Since the P value
obtained in this Cox model does not reflect the uncertainty inherent in the treatment-effect
parameter ψ, the P value obtained in the conventional ITT analysis was used with the HR
obtained following RPSFT analysis (18, 19).
Results
From December 2003 through January 2005, 312 patients from Europe, the USA, Australia,
and Asia were enrolled and randomized (2:1; sunitinib, n = 207; placebo, n = 105) in
double-blind fashion. The double-blind phase was terminated in January 2005 when a
planned interim analysis revealed significantly longer TTP for those randomized to sunitinib
versus placebo (10). Following the interim analysis, enrollment continued through May
2005, ultimately with 361 patients from 56 sites randomized to either sunitinib (n = 243) or
placebo (n = 118); both arms were well balanced for demographic and prior imatinib
treatment characteristics (Table 1). Patient disposition and flow throughout the study are
shown in Supplementary Fig. S2. This report presents data analysis from the full ITT
population of 361 patients.
Randomized patients who received drug per protocol prior to unblinding of study
medication included 228 in the sunitinib and 114 in the placebo arms, respectively
(Supplementary Fig. S2). Sixty-three percent of placebo patients received open-label
sunitinib following disease progression. All patients ultimately discontinued blinded
treatment (reasons shown in Supplementary Fig. S2); 63% and 87% of sunitinib and placebo
patients, respectively, received open-label sunitinib. By study end, among the 255 patients
who received open-label sunitinib, 246 had discontinued treatment, primarily due to disease
progression (68%) or Aes (20%; Supplementary Fig. S2), the most common of which were
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abdominal pain, fatigue, and thrombocytopenia (each n = 4). Nine patients (4%) completed
study treatment and enrolled in a continuation protocol.
Treatment was administered across the double-blind and open-label phases of the trial for a
median of 22 weeks (range, 0.4–170) among the 241 patients who were randomized to the
sunitinib arm and received blinded and/or open-label sunitinib (Table 2). Dosing
interruptions and/or dose reductions in this group were required in 42% and 28% of patients,
respectively.
Efficacy
Over the entire trial including open-label treatment, with median follow-up of 41.7 months
(95% confidence interval [CI], 40.3–43.8), median OS for the sunitinib versus placebo arms
was 72.7 weeks (95% CI, 61.3–83.0) versus 64.9 weeks (95% CI, 45.7–96.0), respectively
(Fig. 1A, Table 3) as estimated using the Kaplan–Meier method (with 28% and 24% of
patients alive, respectively). It is important to note that the “placebo arm” results in this
analysis included survival data for patients who received open-label sunitinib (i.e., 103 of
118 patients randomized [87%]; Supplementary Figs. S2 and S3), and this difference was
not statistically significant (P = 0.306; HR, 0.876; 95% CI, 0.679–1.129; Table 3). To
correct for the expected confounding impact on survival of crossover of placebo-treated
patients to open-label sunitinib, an exploratory analysis of OS was performed using the
RPSFT method, which calculated a median OS for the placebo arm of 39.0 weeks (95% CI,
28.0–54.1; Fig. 1A, Table 3). In this exploratory analysis, sunitinib nearly (1) doubled
median OS and (2) halved the hazard of death versus placebo (HR, 0.505; 95% CI, 0.262–
1.134; P = 0.306; Table 3).
The median TTP among all patients in the final ITT population was 26.6 weeks (95% CI,
16.0–32.1) versus 6.4 weeks (95% CI: 4.4–10.0) in the sunitinib versus placebo arms,
respectively (Table 3). Patients in the placebo arm exhibited an almost three-fold greater risk
of disease progression compared with those randomized to sunitinib treatment (HR, 0.339;
95% CI, 0.244–0.472; P ≤0.001). Similar results were obtained for PFS (Table 3). At final
analysis, among the 99 placebo-treated patients who subsequently received open-label
sunitinib treatment (Supplementary Fig. S2), median TTP was 10.4 weeks (95% CI, 4.3–
22.0) on open-label sunitinib treatment.
Partial responses (PRs) were observed in 16 sunitinib-treated patients (ORR, 7%) versus
none in placebo-treated patients (Table 3). The ORR among placebo-treated patients who
subsequently received open-label sunitinib treatment was 10%, comprising 9 PRs and 1
complete response.
Safety
Safety results across the entire study are presented in Table 4. Results shown for the double-
blind phase differ from the previously reported interim analysis (10) only by the inclusion of
results for patients randomized subsequent to the interim analysis. Sunitinib-treated patients
during the double-blind phase had relatively short-term exposure to the drug (median 8
weeks of drug; Table 2). In contrast, the 241 patients who were randomized to and received
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blinded and/or open-label sunitinib treatment represent the group with the greatest
longitudinal exposure to sunitinib (median 22 weeks on drug). In this group, the most
common treatment-related non-hematologic AEs were fatigue (47%), diarrhea (43%), and
nausea (37%; Table 4). The most frequent treatment-related non-hematologic grade 3/4 AEs
among these patients were fatigue (10%), hypertension (8%), and hand–foot syndrome,
asthenia, and diarrhea (5% each). The frequencies of non-hematologic AEs in these patients
who received extended sunitinib therapy were slightly higher than those reported in the
sunitinib arm during the double-blind phase.
The frequency of treatment-related hypertension (any grade) on sunitinib increased from
12% during blinded treatment to 20% across the entire study. In contrast, the frequency of
treatment-related cardiac AEs overall was 11% during the double-blind phase and 12% over
the entire study (comprising decreased ejection fraction [8%] and left ventricular
dysfunction [2%] as the most frequent events). Over the course of the study, one patient
experienced congestive heart failure (grade 2) that was considered related to sunitinib
treatment; this event resolved during a dosing delay with appropriate supportive therapy.
The rate of treatment-related hypothyroidism (all grades) increased with extended sunitinib
treatment from 3% during the double-blind phase to 13% for the entire trial.
Hypothyroidism did not result in any treatment discontinuations.
Hematologic laboratory abnormalities among patients who received sunitinib across the
entire study included reduced levels of hemoglobin (60%), neutrophils (59%), and platelets
(41%). Most of these abnormalities were grade 1/2 and were similar in frequency to those
seen during blinded sunitinib treatment.
During blinded treatment, four treatment-related deaths were reported in the sunitinib arm
(2%; cardiac arrest, cerebral ischemia, left ventricular failure, and multi-organ failure) and
two (2%; cardiac arrest, gastrointestinal hemorrhage) in the placebo arm. Additionally, four
treatment-related deaths were reported during open-label sunitinib treatment or follow-up
(hepatic encephalopathy, hepatic failure, melena, and pneumonia [as coded from the
Medical Dictionary for Regulatory Activities]).
Circulating biomarkers of angiogenesis
Levels of plasma VEGF-A, sVEGFR-2, and sVEGFR-3 were measured on days 1 and 28 of
cycles 1–3 (i.e., after 2 weeks off treatment and after 4 weeks on treatment, respectively)
and on cycle 1 day 14 (C1;D14) in a subset of patients in both study arms. Overall, this
patient subset was similar to the ITT population with regard to baseline demographic and
prior imatinib treatment characteristics, with the two treatment arms generally well balanced
for these parameters (Table 1). Exceptions were higher percentages of patients with
metastases in the liver or peritoneum in both treatment arms and a higher proportion of men
in the placebo arm of the biomarker subset compared with the ITT population.
Changes from baseline in plasma levels of VEGF-A, sVEGFR-2, and sVEGFR-3 correlated
with sunitinib treatment on this intermittent dosing schedule (Supplementary Fig. S4), as has
been reported in other sunitinib studies (13–15). In the placebo arm, there were no
significant changes in the levels of these proteins at any time point. Between-treatment
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differences were significant (P < 0.001) at all time points tested after treatment initiation
(except for VEGF-A on C2;D1 and C3;D1).
Possible associations between levels of VEGF-A, sVEGFR-2, or sVEGFR-3 and clinical
outcomes (TTP or OS) were also evaluated at these time points (Supplementary Tables S1
and S2). Significant associations are shown in Fig. 2. In the sunitinib arm, low baseline
levels (below median) of sVEGFR-2 and reduced levels on C1;D14 relative to baseline were
associated with significantly prolonged TTP and OS (Figs 2A–D). Reductions in sVEGFR-3
on C1;D14 compared with baseline were also associated with longer TTP (Fig. 2E). In the
placebo arm, reductions in VEGF-A relative to baseline were significantly associated with
longer TTP for both C1;D28 (Fig. 2F) and C2;D1 (Supplementary Table S1). No other
significant associations between plasma VEGF-A, sVEGFR-2, or sVEGFR-3 levels and
TTP or OS through C3;D28 were found.
The predictive value of the ratio of each plasma protein biomarker to baseline at each time
point analyzed and other baseline patient characteristics (age, sex, ECOG PS, time since
diagnosis, maximum daily dose of prior imatinib treatment, and baseline tumor size) was
assessed in uni- and multivariate analyses of the two treatment arms separately as well as in
the entire population. Several parameters were found to have significant associations with
TTP or OS in univariate analyses in one arm or the other. However, in multivariate analysis,
significant associations were only found between OS in the sunitinib arm and baseline tumor
size, baseline sVEGFR-2, and sVEGFR-2 C1;D14 ratio to baseline (Supplementary Table
S3).
Discussion
These longer-term analyses from this large randomized, placebo-controlled, multicenter
study provide new insights into the significant clinical activity of sunitinib in imatinib-
resistant/intolerant GIST patients. The trial was designed with TTP as the primary endpoint,
with the expectation that the majority of patients assigned to placebo would subsequently
cross over to open-label sunitinib. In an earlier analysis that reflected the double-blind phase
of the trial, sunitinib resulted in significantly longer OS versus placebo (HR, 0.49; 95% CI,
0.29–0.83; P = 0.007; ref. 10). In the final analysis following all crossovers, Kaplan–Meier
estimates of OS for the two treatment arms converged, with 87% of patients randomized to
placebo successfully able to receive sunitinib following progressive disease or unblinding.
This crossover study was not powered to show an OS difference, as crossover patients were
still regarded as part of the ITT placebo arm for the purpose of survival analysis, since the
comparison was based on the randomization. Exploratory analysis using the RPSFT method
suggested that sunitinib confers a long-term OS benefit relative to placebo. With this
method, the estimated median OS for patients in the sunitinib arm was almost twice that of
patients in the placebo arm (72.7 versus 39.0 weeks). Using RPSFT analysis to “correct for
crossover,” this analysis estimated an HR (0.505; 95% CI, 0.262–1.134) that was further
from the null than that obtained using conventional statistical methods (0.876; 95% CI,
0.679–1.129), as expected given that crossover would reduce the treatment-effect size
between the two arms. The data obtained by this method were highly consistent with those
obtained for blinded placebo treatment in the interim analysis using conventional methods
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(Fig. 1B), supporting the validity of this method. RPSFT analysis also avoids potential
biases introduced through subgroup analyses, since it is based on the ITT population.
Overall, the patients who crossed over from placebo to open-label sunitinib demonstrated
benefits that were only somewhat more limited than those of patients initially randomized to
blinded sunitinib treatment, validating the placebo-controlled crossover design of the study.
However, there was some indication that delaying initiation of sunitinib treatment compared
unfavorably to earlier dosing with sunitinib, as median TTP after crossover in the placebo
arm was 10.4 weeks.
Sunitinib exhibited a safety profile consistent with prior reports over the extended course of
this study, and AEs were generally manageable and reversible using standard medical
therapy with or without dosing interruption and/or dose reduction. Without having
specifically analyzed the timing or duration of AEs, the results showed that while the
frequency of non-hematologic AEs increased slightly with long-term sunitinib treatment,
there were no major changes in the overall safety profile. Fatigue remained the most
commonly reported AE (Table 4), although a large proportion of fatigue in this population
may be attributable to the burden of advanced GIST given the frequency of this AE reported
in the placebo arm during the double-blind phase. As with other angiogenesis inhibitors
(20), the frequency of hypertension increased with extended sunitinib treatment, while the
incidence of other cardiac AEs did not increase. Indeed, the most frequent of these
(“decreased ejection fraction”) appeared to occur primarily during the double-blind phase of
the trial (8% versus 1% during open-label treatment, with the caveat that while regularly
scheduled periodic assessments of cardiac function were only mandated during the double-
blind phase of the study, such assessments were conducted if clinically indicated to monitor
patients on this trial at all times). As expected with sunitinib (9, 21), the incidence of
hypothyroidism increased with time on treatment from 3% during the double-blind phase to
13% for the entire trial (and thyroid dysfunction may have been under-reported because
thyroid-stimulating hormone levels were not required to be monitored prospectively).
However, most cases were mild to moderate in severity (11%) and easily managed using
thyroid hormone replacement therapy.
A secondary objective of this trial was to examine potential correlations between clinical
outcomes and plasma biomarkers of angiogenesis that are related to known molecular
targets of sunitinib. The plasma pharmacodynamics of VEGF-A, sVEGFR-2, and
sVEGFR-3 during 4-week-on/2-week-off sunitinib dosing were similar to those previously
reported for these proteins in renal cell carcinoma, hepatocellular carcinoma, and breast
cancer (13–15). In the present study, no consistent associations were observed between
changes in plasma levels of these angiogenesis-related proteins and either TTP or OS. These
findings contrast markedly with the strong associations obtained at several time points
between reductions in plasma levels of sKIT and improved clinical outcome that have been
reported previously in the present study (11) and in a phase II GIST study in which sunitinib
was administered on a continuous daily dosing schedule (22). Taken together, these findings
for circulating proteins related to molecular targets of sunitinib support the view that
inhibition of activated KIT represents the primary mechanism for the clinical activity of this
multitargeted tyrosine kinase inhibitor in GIST (23).
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In conclusion, these efficacy and safety results from the complete longitudinal data of this
worldwide phase III study further support prior reports that sunitinib provides significant
clinical benefit to GIST patients whose disease is resistant to, or who are intolerant of,
imatinib therapy.
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Translational Relevance
We present complete longitudinal analyses, including final overall survival (OS), from
the pivotal phase III study that led to regulatory approval of sunitinib in patients with
advanced imatinib-resistant/intolerant gastrointestinal stromal tumor (GIST). We
demonstrate the confounding effect of the study’s crossover design (patients could switch
from placebo to sunitinib) on OS: conventional intent-to-treat analysis showed that OS
converged in the treatment arms, showing no statistical difference, despite statistically
significant differences in tumor control rates. However, using the exploratory rank-
preserving structural failure time method to model the absence of crossover, we
estimated that sunitinib conferred a long-term OS benefit relative to placebo (73 versus
39 weeks). We also analyzed circulating biomarkers of angiogenesis during sunitinib
treatment and found no consistent associations with clinical outcome. Finally, these long-
term exposure data showed that no new safety concerns emerged with extended sunitinib
treatment.
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Fig. 1.
OS across the entire study: A, final analysis; B, final and interim analyses. KM, Kaplan–
Meier method; RPSFT, rank-preserving structural failure time method.
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Fig. 2.
Significant associations found between levels of circulating biomarkers of angiogenesis and
TTP or OS. A–E, sunitinib arm. F, placebo arm. Median values used for stratification: A, B
(baseline sVEGFR-2), 9,159 pg/mL; C, D (sVEGFR-2 ratio to baseline, C1;D14), 0.727; E
(sVEGFR-3 ratio to baseline, C1;D14), 0.694; F (VEGF-A ratio to baseline, C1;D28),
0.957.
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Table 1
Baseline patient characteristics and prior imatinib treatment history
ITT population Biomarker subset
Sunitinib (n = 243) Placebo (n = 118) Sunitinib (n = 88) Placebo (n = 60)
Median age, years (range) 57 (23–84) 55 (23–81) 57 (28–81) 55 (26–81)
Sex, n (%)
 Male 152 (63) 71 (60) 52 (59) 41 (68)
 Female 91 (37) 47 (40) 36 (41) 19 (32)
ECOG performance status, n (%)
 0 109 (45) 53 (45) 42 (48) 30 (50)
 1 131 (54) 63 (53) 45 (51) 30 (50)
 2 3 (1) 2 (2) 1 (1) 0 (0)
Median tumor burden,* mm (range) 227 (18–722) 240 (29–749) 218 (45–707) 243 (29–749)
Most common metastatic sites, n (%)
 Liver mass/nodule 138 (57) 68 (58) 67 (76) 44 (73)
 Peritoneal mass/nodule 100 (41) 45 (38) 44 (50) 29 (48)
 Mesenteric adenopathy 26 (11) 15 (13) 11 (13) 11 (18)
Previous imatinib therapy
 Median maximum daily dose, mg (range) 800 (300–1,600) 800 (400–1,600) 800 (300–1,600) 800 (400–1,600)
 Median cumulative treatment duration, weeks (range) 107 (0.3–206) 108 (11–231) 104 (7–195) 105 (12–174)
 Treatment outcome, n (%)
  Progression ≤6 months 42 (17) 20 (17) 16 (18) 10 (17)
  Progression >6 months 188 (77) 94 (80) 68 (77) 47 (78)
  Intolerance 13 (5) 4 (3) 4 (5) 3 (5)
 Best response, n (%)
  Complete response 9 (4) 1 (1) 3 (3) 0 (0)
  Partial response 62 (26) 43 (36) 20 (23) 22 (37)
  Stable disease 97 (40) 40 (34) 44 (51) 20 (33)
  Progressive disease 68 (28) 32 (27) 18 (21) 17 (28)
  Not applicable/missing 7 (3) 2 (2) 2 (2) 1 (2)
Time since diagnosis
 Median, years (range) 3.2 (0.2–26.8) 3.3 (0.2–16.4) 3.2 (0.2–15.7) 3.2 (0.5–9.5)
*Sum of longest diameters of target lesions.
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